Teriparatide

Evidence Level: L5

Predicted Indications: 9

Teriparatide

Pharmacist Assessment Report

Teriparatide: From Postmenopausal Osteoporosis to duodenal ulcer (disease)

One-Sentence Summary

Teriparatide is a parathyroid hormone fragment (PTH 1-34) used to treat osteoporosis in patients at high risk of fracture. The TxGNN model predicts it may be effective for duodenal ulcer, but no clinical trials and no publications currently support this prediction, so it rests on the score from the TxGNN model (deep learning) alone, which may reflect similarities the model learned between related diseases, not biological evidence.

Quick Overview

Item	Content
Original Indication	Postmenopausal osteoporosis / osteoporosis
Predicted New Indication	Duodenal ulcer
TxGNN Prediction Score	0.9986
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Teriparatide is a synthetic fragment of human parathyroid hormone. It acts on the PTH1 receptor (and also binds the PTH2 receptor) to stimulate new bone formation. This is why it is used for osteoporosis. Detailed mechanism-of-action data beyond these receptor targets are not available.

Based on the data compiled for this report, no mechanistic link was identified between PTH1 receptor-driven bone formation and duodenal ulcer. The two conditions differ in tissue, cause, and disease process: one is bone fragility, the other is damage to the lining of the upper intestine. The high TxGNN score (0.9986) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological or clinical support. Without trials or literature, this prediction should be treated as a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Teriparatide is widely marketed in India, with 20 valid registrations, all single-ingredient injectable products and none cancelled. Approved indication text was not available for these registrations. Five main products are listed below.

Authorization Number	Product Name	Dosage Form	Manufacturer
28520	Bonspark Injection	Cartridge of 3 ml injection	Integrace Pvt Ltd
215049	Tricium PTH Injection	Cartridge of 3 ml injection	Corona Remedies Pvt Ltd
214816	Terifrac Injection	Cartridge of 1 injection	Intas Pharmaceuticals Ltd
161859	Osteri 750mcg Solution for Injection	Pre-filled pen of 3 ml	Emcure Pharmaceuticals Ltd
94276	Gemtide Injection	Pre-filled pen of 2.4 ml	Alkem Laboratories Ltd

Safety Considerations

Disease associations flagged in the knowledge graph (contraindication-type links, not label text): hypercalcemia, hyperparathyroidism, bone Paget disease (including juvenile), bone osteosarcoma, nephrocalcinosis, urolithiasis, phosphorus metabolism disease, osteomalacia, rickets, renal osteodystrophy, osteitis fibrosa, and hypotensive disorder.
Drug interactions (8 entries found):
- Moderate: digoxin, digitoxin, topical calcitriol, topical calcipotriol
- Minor: hydrochlorothiazide, furosemide
Two further entries (PTH1 and PTH2 receptors) are pharmacological target records, not interactions.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The duodenal ulcer prediction has no trials, no literature, and no plausible mechanism. The high score alone is not enough to justify further investment.

To proceed, the following is needed:

A biological rationale linking PTH1 receptor signalling to duodenal mucosal disease
Preclinical or mechanistic studies showing any effect on ulcer healing
Package insert warnings and contraindications for a formal safety screen

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.